Open AccessPlatelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
Author(s) -
Adam Corken,
Jerry Ware,
Junqiang Dai,
John M. Arthur,
Susan S. Smyth,
Clayton L. Davis,
Juan Liu,
Terry Harville,
Milind A. Phadnis,
J. L. Mehta,
Yasir Rahmatallah,
Nishank Jain
Publication year - 2022
Publication title -
kidney360
Language(s) - English
Resource type - Journals
ISSN - 2641-7650
DOI - 10.34067/kid.0005532022
Subject(s) - platelet , medicine , kidney disease , platelet activation , aspirin , renal function , inflammation , mean platelet volume , monocyte , immunology , endocrinology
Chronic kidney disease (CKD) is characterized by dysregulated inflammation that worsens with CKD severity. The role of platelets in modulating inflammation in stage 4 or 5 CKD remains unexplored. We investigated whether there are changes in platelet-derived thromboinflammatory markers in CKD with dual antiplatelet therapy (DAPT; aspirin 81 mg/d plus P2Y12 inhibitor).